Longevity & AgingNewLimit Raises $435M to Bring Epigenetic Age-Reprogramming Therapy to Human Trials
NewLimit, a longevity biotech, has raised $435 million and plans to begin human clinical trials of an age-reprogramming therapy next year — a milestone previously thought to be a decade away. The company's lead therapy targets the liver, helping older liver cells behave more like younger ones through epigenetic reprogramming. In preclinical studies, treated older liver cells reversed measurable signs of cellular aging and showed improved resilience under stress. The first human trial will focus on fatty liver disease. Backed by major investors including Founders Fund and Eli Lilly Ventures, NewLimit represents a significant step toward translating longevity science from the lab into real clinical medicine, with potential implications for metabolic disease, cardiovascular health, and immune decline.
